

# Progenics Cord Blood Cryobank Annual Quality Report



2019



# Company Profile

---

Progenics Cord Blood Cryobank is a leader in delivering consistent, high quality cord blood processing results, with over 15 years of experience in the cord blood banking industry. Progenics is AABB Accredited and is registered with both Health Canada and the Food and Drug Administration (FDA) in the United States. The company's mission is to provide the highest quality processing and long-term safe, secure storage of cord blood stem cells, to ensure their availability when needed.

Progenics Cord Blood Cryobank's *modified double stem cell extraction processing technique*, developed by the company's Research and Development Team, ensures that they can guarantee every processed cord blood sample will have a minimum yield of 85% Total Nucleated Cells (TNC).

## Contact Us:

1-866-921-1666

[info@progenics.ca](mailto:info@progenics.ca)

[www.progenics.ca](http://www.progenics.ca)

701 Sheppard Avenue East  
Suite 310,  
Toronto, ON  
M2K 2Z3  
Canada

## Report Summary

---

This quality report summarizes the processing results from all the cord blood samples processed by Progenics Cord Blood Cryobank from January 01, 2019 to December 31, 2019. The quality indicators referenced in this report present 3 key variables: the yield of total nucleated cells (TNC); total nucleated cell viability, and; CD34+ viability.

This report also compares the average monthly and annual percentage yields of TNC including stem cells, the average percentage of total viable nucleated cells, and the average percentage of viable CD34+.

Progenics uses a *modified double stem cell extraction processing technique* which ensures that a higher number of viable nucleated cells are banked for potential medical need. Based on this technique, the average recovery rate for TNCs banked has been 97.65%, which is significantly greater than the industry average and the guaranteed quality standard Progenics offers to each client.

## 2019 Monthly Report

Progenics Cord Blood Cryobank 2019 Monthly Report			
Month	Total Nucleated Cells (TNC) Yield (%)	Total Viable Nucleated Cells TVNC (%)	CD34+ Viability (%)
January	97.82	95.30	99.28
February	95.94	94.92	99.17
March	97.65	93.99	98.86
April	97.93	93.42	99.06
May	98.37	94.22	99.09
June	98.14	94.92	99.35
July	98.16	93.98	99.45
August	98.33	94.64	99.22
September	97.75	93.80	99.50
October	97.48	93.37	99.31
November	97.84	92.98	99.15
December	96.59	92.53	99.43
Annual average	<b>97.67</b>	<b>94.01</b>	<b>99.24</b>

### Notes:


**TNC** TNC includes all nucleated cells such as stem cells and nucleated red blood cells.

**TVNC** Viability of total nucleated cells

**CD34+** Hematopoietic progenitor cells

**Viability** Cell viability is a determination of whether cells are living or dead, based on a total cell sample. The viability of cells is evaluated by either measurement of cell membrane integrity or by measuring certain functions of the cells from a total cell sample.

## Progenics Cord Blood Cryobank 2019 Monthly Report



**Notes:**

- TNC** TNC includes all nucleated cells such as stem cells and nucleated red blood cells.
- TVNC** Viability of total nucleated cells
- CD34+** Hematopoietic progenitor cells
- Viability** Cell viability is a determination of whether cells are living or dead, based on a total cell sample. The viability of cells is evaluated by either measurement of cell membrane integrity or by measuring certain functions of the cells from a total cell sample.

## Conclusion: Comparing Annual Averages

Based on the above data, we can confidently report that for 2019:

- ✓ The average annual percentage yield of **total nucleated cells (TNC)** was: **97.67%**
- ✓ The average annual percentage of **total viable nucleated cells** was: **94.01%**
- ✓ The average annual percentage of **viable CD34<sup>+</sup>** cells was: **99.24%**

The above results have been made possible due to our *modified double stem cell extraction processing technique* which surpasses our internal quality standards by over 10%.

Progenics quality guarantee policy assures that processed cord blood units (CBU) will contain a minimum of 85% yield of total nucleated cells (TNC). Once a client's CBU has been processed, and all processing parameters meet our cord blood bank acceptance criteria, the client will receive a *Certificate of Cryopreservation* which contains quality indicators of cord blood processing results.

After reviewing the data within this report, we can confidently claim that we offer our clients the highest consistent cord blood processing results.